CIK 0001880438
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 820606654
- Phone
- +1 650-331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- 4 Grant or award Director acquired 11,875 shares (grant or award)
- 4 Grant or award Director acquired 3,750 shares (grant or award)
- 4 Open-market sale 10% owner sold 200,000 shares at $1.09 ($218,000)
- 4 Open-market buy Chief Executive Officer bought 10,000 shares at $1.07 ($10,665)
- 4 Open-market sale 10% owner sold 2,532,000 shares at an average $1.13 ($2,872,477)
- 4 Open-market buy Director bought 8,610 shares at $1.18 ($10,133)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 10,523 shares (grant or award)
- 4 Grant or award Director acquired 9,705 shares (grant or award)
- 4 Grant or award Director acquired 3,065 shares (grant or award)
- 4 Grant or award Director acquired 9,705 shares (grant or award)
- 4 Grant or award Chief Development Officer acquired 50,250 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 46,500 shares (grant or award)
Page 4 of 11 · 216 filings